Disclosure of payments made to HCPs


Engaging with healthcare professionals

As a healthcare company, GSK regularly works with healthcare professionals. From collaborating on clinical trials to providing high quality, balanced information about our medicines and vaccines, in all of our interactions we aim to be transparent about our work, operate with integrity, and always put the interests of patients first.

Our policy for working with healthcare professionals

On the 1st of January 2016, we announced a series of changes to our policy for how we work with healthcare professionals (HCPs). The purpose of these changes is to improve understanding of new data and clinical experience with our products and increase transparency of payments to HCPs. The changes will apply to innovative products for a limited time and aim to support HCPs to deliver better outcomes for patients.

Disclosure of payments made to HCPs

We acknowledge the importance of increased transparency and of putting the patient at the centre of every decision we take. We remain committed to disclosing the payments we make to HCPs and intend to expand our reporting of payments to individual HCPs.

We already publish payments made to HCPs in 32 markets across Europe (including Russia and Ukraine) as well as Australia, Japan and the US for activities such as advisory boards, scientific symposiums and market research.

From 2019, where legally permitted, we will now report individual level payments made each year to HCPs for attending educational meetings and for the provision of services, such as speaking at events or attending advisory boards. Where individual level disclosure is not legally permitted, we will continue to report aggregate payments.

Disclosure Data for Taiwan

Click here for disclosure of payments made to HCPs in Taiwan

For more information, visit gsk.com.

Document Number: NP-TW-NA-WCNT-200001